•  
  •  
  •  
  •  

2026-07-22 17:30:25

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Trishakti Industries Ltd announces Strategic Expansion into the United Arab Emirates & Kingdom of Saudi Arabia
  • Talbros Engineering Ltd secures new industrial premises for expansion
  • JD Cables Limited - Q1 FY27 Business Update
  • Bajel Projects Formalises Landmark 500 kV Transmission Line Agreement with EETC in Cairo, Egypt
  • IIFL Finance Reports Strong Q1 FY27 Performance: Net Profit Surges 160% to ₹713 Crore

Keywords Selected:  IoT

Research

  • Q2FY22 Result Update - Biocon Ltd - ICICI Direct

IPO News

  • Concord Biotech Limited's IPO to open on Friday, 4th August, 2023, sets price band at ₹705 to ₹741 per Equity Share
  • Windlas Biotech Ltd posts consolidated PAT of Rs. 11.44 crores in Q4FY23
  • Ahmedabad-based Concord Biotech gets SEBI nod for IPO
  • Rare Enterprises and Quadria Capital-backed Concord Biotech files DRHP for IPO

Stock Report

  • Rossari Biotech Limited Posts Steady Q1 FY27 Growth: Net Profit Rises to ₹350.95 Million
  • Vivo Bio Tech Limited Announces Q1 FY27 Results; Net Profit Rebounds Sequentially to ₹18.76 Lakhs
  • Fermenta Biotech Ltd receives FSSAI nod for its product Vitamin D3 (Cholecalciferol) - Plant Source
  • Optiemus Electronics to manufacture Quectel wireless modules in India
  • Concord Biotech Ltd successfully completes PPB and NDA inspection
  • Biocon Reinforces Commitment to Diabetes Care in Malaysia as Partner Duopharma Biotech Secures Insulin Tenders
  • Concord Biotech Ltd completes ANVISA Inspection conducted by the Brazilian Health Regulatory Agency at the Limbasi API Manufacturing Facility
  • Concord Biotech Ltd receives ANDA approval for Tofacitinib Tablets, 5 mg and 10 mg
  • Concord Biotech Ltd receives ANDA approval from USFDA for Mycophenolate Mofetil for Oral Suspension USP
  • Panacea Biotec Ltd posts consolidated PAT of Rs. 52 lakhs in Q4FY26
  • CDSCO grants marketing authorization to Wockhardt's breakthrough antibiotic, ZAYNICH®
  • Biocon Pharma Limited Receives Health Canada Approval for Micafungin for Injection, USP, 50 MG and 100 MG
  • Brigade Hotel Ventures Ltd and Marriott International Open Courtyard by Marriott Kochi Infopark
  • Espire Hospitality Ltd enters into agreement with Marriott International to manage its upcoming 'JW Marriott Resort & Spa' near Vrindavan
  • IKIO Technologies Ltd Q4 FY2026 consolidated PAT rises to Rs. 16.48 crores
  • Rossari Biotech Ltd consolidated Q4 FY2026 PAT climbs to Rs. 45.96 crores
  • Rossari Biotech Ltd recommends final dividend of Rs. 0.50
  • Biocon Receives Health Canada Approval of Bosaya™ and Vevzuo™, Biosimilars to Prolia® and Xgeva®
  • Windlas Biotech Announces ₹47 Crore Share Buyback at ₹1,000 per Share
  • Avio Smart Market Stack Signs MoU with UAL Biotech to Advance Sustainable Agriculture in India
  • Panacea Biotec Ltd receives LoA from CMSS
  • Indrayani Biotech Limited Finalizes Terms for ₹49.90 Crore Rights Issue
  • Biocon Pharma Ltd receives U.S. FDA Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • Unitop Chemicals Pvt Ltd commissions 15000 MTPA ethoxylation capacity

Industry News

  • Semicon startup Netrasemi raises Rs 10 crore in Pre Series A round from Unicorn India Ventures to build Edge AI
  • Samsung Innovation Campus Upskills 3,000 Less-Privileged Students Across India in AI, IoT, Big Data and Coding & Programming

Latest Post

  • Trishakti Industries Ltd announces Strategic Expansion into the United Arab Emirates & Kingdom of Saudi Arabia
  • Talbros Engineering Ltd secures new industrial premises for expansion
  • JD Cables Limited - Q1 FY27 Business Update
  • Bajel Projects Formalises Landmark 500 kV Transmission Line Agreement with EETC in Cairo, Egypt
  • IIFL Finance Reports Strong Q1 FY27 Performance: Net Profit Surges 160% to ₹713 Crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025